Recent deep sequencing work has demonstrated that point mutations, copy number loss and structural variants of CRBN can impair responses to lenalidomide and pomalidomide, and that these aberrations significantly reduce the survival of MM patients [45]. Here, CRBN is linked to Miyoshi myopathy.